AC Immune

Company Overview

A clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases through integrated diagnostic and therapeutic platforms targeting Alzheimer's, Parkinson's, and rare neurological conditions. The company develops both diagnostic tools and therapeutics using multiple modalities including antibodies, active immunotherapies, and small molecule drugs. AC Immune focuses on validated therapeutic targets in neurodegeneration with a precision medicine approach that combines companion diagnostics with targeted treatments.

Headquarters and Global Presence

AC Immune is headquartered in Lausanne, Switzerland, at the EPFL Innovation Park. The company operates as a global leader in neurodegenerative disease research with international partnerships and collaborations. Its location provides access to scientific excellence and skilled workforce from the leading Swiss research ecosystem.

Founding and History

AC Immune was founded in 2003 at the EPFL Innovation Park in Lausanne, strategically positioned to leverage Switzerland's biotechnology infrastructure. The company has built a track record of innovation in neurodegeneration over two decades. AC Immune is publicly traded on NASDAQ under the ticker ACIU, providing access to capital markets for advancing its precision medicine programs.

Therapy Areas and Focus

The company focuses primarily on major neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, along with certain rare neurological indications. AC Immune addresses the significant unmet medical need in neurodegeneration where few effective treatments exist. The precision medicine approach aims to match specific patient populations with targeted therapies based on underlying disease biology. This strategy spans nervous system diseases as well as endocrinology and metabolic conditions related to neurodegeneration.

Technology Platforms and Modalities

AC Immune operates two proprietary technology platforms that enable discovery and development of both diagnostics and therapeutics for neurodegenerative diseases. The platforms generate multiple treatment modalities including therapeutic antibodies, active immunotherapies, small molecule drugs, and radiopharmaceutical diagnostics. This integrated approach allows the company to develop companion diagnostics alongside targeted treatments. The technology focuses on validated targets in neurodegeneration, enabling precision medicine strategies that match patients to optimal therapies.

Key Pipeline and Programs

The company's clinical pipeline includes 15 active clinical trials across its integrated diagnostic and therapeutic programs. Key assets include ACI-7104 and the diagnostic agent Izaflortaucipir (18F) for tau imaging in neurodegenerative diseases. The pipeline uniquely combines diagnostic radiopharmaceuticals with therapeutic candidates targeting the same biological pathways. Programs span from early-stage discovery through clinical development, with multiple assets advancing through Phase I and Phase II trials in Alzheimer's disease and related indications.

Key Personnel

The company is led by an experienced management team with deep expertise in neurodegenerative disease drug development. Leadership includes executives with backgrounds in both biotechnology and pharmaceutical industries focused on CNS therapeutics. The scientific team combines expertise in immunotherapy, diagnostics, and precision medicine approaches to neurodegeneration.

Strategic Partnerships

AC Immune has established strategic partnerships to advance its precision medicine programs in neurodegeneration. The company collaborates with pharmaceutical and biotechnology partners for development and commercialization of its diagnostic and therapeutic candidates. These partnerships leverage AC Immune's proprietary platforms while providing access to resources and expertise for advancing programs through clinical development. The collaborative approach enables the company to pursue multiple programs across its integrated diagnostic-therapeutic strategy.

FAQ Section